Mycophenolate mofetil added to immunosuppression after liver transplantation – first results

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Transplant International

• Publication date

  1997-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S001470050046PMID 9163864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rescue therapy with mycophenolate mofetil. Mycophenolate Mofetil Renal Refractory Rejection Study Group.

  1996cited by this paper
• Mycophenolate mofetil for maintenance therapy in kidney transplantation

  1996cited by this paper
• Mycophenolate mofetil in liver transplantation

  1996cited by this paper
• From mice to man: the preclinical history of mycophenolate mofetil

  1996cited by this paper
• PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation.

  1994cited by this paper
• Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.

  1994cited by this paper
• Effect of mycophenolate mofetil on allograft arteriosclerosis (chronic rejection).

  1994cited by this paper
• Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil.

  1994cited by this paper
• Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.

  1994cited by this paper
• Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease.

  1994cited by this paper
• Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil

  1993cited by this paper
• Immunosuppressant combinations in primate cardiac xenografts. A review.

  1993cited by this paper
• THE USE OF MYCOPHENOLATE MOFETIL (RS‐61443) IN HUMAN HEART TRANSPLANT RECIPIENTS

  1993cited by this paper
• RS-61443 for treatment-resistant human liver rejection.

  1993cited by this paper
• Effects of immunosuppressive therapy on the rat aortic allograft model.

  1993cited by this paper
• Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation.

  1993cited by this paper
• RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival.

  1993cited by this paper
• Mycophenolate mofetil (RS-61443): Mechanisms of action and effects in transplantation

  1993cited by this paper
• Mycophenolate mofetil, a rationally designed immunosuppressive drug

  1993cited by this paper
• Immunosuppressant Combinations in Primate Cardiac Xenografts a

  1993cited by this paper
• RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection

  1992cited by this paper
• RS-61443--a new, potent immunosuppressive agent.

  1991cited by this paper
• RS-61443 reverses acute allograft rejection in dogs.

  1991cited by this paper
• Prolongation of dog renal allograft survival by RS-61443, a new, potent immunosuppressive agent.

  1991cited by this paper
• Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis.

  1990cited by this paper
• Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety.

  1987cited by this paper

• Post-Transplant Hepatocellular Carcinoma: Balancing Immunosuppression and Immune Checkpoint Inhibitors.

  2026cites this paper
• Global research hotspots and trends of acute rejection after liver transplantation from 1988 to 2022: a bibliometric analysis

  2024cites this paper
• Esdeveniments adversos posteriors a la colangiopancreatografia retrograda endoscòpica en els pacients amb cirrosi hepàtica i en els receptors de transplantament hepàtic

  2019cites this paper
• Immunosuppression

  2018cites this paper
• Management of Immunosuppression in Liver Transplantation.

  2017cites this paper
• Neurotoxicity of commonly used hepatic drugs.

  2014cites this paper
• Clinical mycophenolic acid monitoring in liver transplant recipients.

  2014cites this paper
• Newer Immunosuppressive Drugs

  2012cites this paper
• Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients

  2011cites this paper
• Renal function after transplantation of the liver and intestine

  2010cites this paper
• Immunosuppression in liver transplantation.

  2009cites this paper
• A Comprehensive Review of Immunosuppression Used for Liver Transplantation

  2009cites this paper
• Calcineurin-Inhibitor-freie Immunsuppression – Mycophenolatmofetil-Monotherapie nach Lebertransplantation

  2008cites this paper
• Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction

  2008cites this paper
• Pharmacokinetics of Mycophenolic Acid in Live Donor Liver Transplant Patients vs Deceased Donor Liver Transplant Patients

  2008cites this paper
• Switch to 1.5 grams MMF monotherapy for CNI‐related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension

  2007cites this paper
• Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

  2007cites this paper
• Repopulation genetisch veränderter Kupffer-Zellen und Evaluation deren Effekte in einem akuten hepatischen Schädigungsmodell

  2007cites this paper
• Long‐term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation

  2006cites this paper
• Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation.

  2006cites this paper
• Indications of Mycophenolate Mofetil in Liver Transplantation

  2005cites this paper
• Future directions in immunosuppression.

  2004cites this paper
• Evolution of immunosuppression in liver transplantation: contribution of cyclosporine.

  2004cites this paper
• MYCOPHENOLATEMOFETIL FOR IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION: A FOLLOW‐UP STUDY OF 191 PATIENTS

  2003cites this paper
• Mechanisms of Pharmacologic Immune Suppression

  2003cites this paper
• Treatment by Mycophenolate Mofetil of Advanced Graft Vascular Disease in Non‐Human Primate Recipients of Orthotopic Aortic Allografts

  2003cites this paper
• A model to predict the development of mental status changes of unclear cause after liver transplantation

  2003cites this paper
• Chronic Rejection after Human Liver Transplantation

  2002cites this paper
• Infections in Renal Transplant Recipients Receiving Mycophenolate Versus Azathioprine-Based Immunosuppression

  2002cites this paper
• Immunosuppression in Solid Organ Transplantation: A Review

  2002cites this paper
• Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study.

  2002cites this paper
• New Immunosuppressive Agents

  2001cites this paper
• Postoperative tracheal extubation after orthotopic liver transplantation

  2001cites this paper
• A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

  2001cites this paper
• Pathogenesis and treatment of bile duct loss after liver transplantation.

  2001cites this paper
• Cardiac Allograft Rejection

  2001cites this paper
• Postoperative Care of the Liver Transplant Patient

  2001cites this paper
• Neurotoxicity of calcineurin inhibitors: impact and clinical management

  2000cites this paper
• The reconstitution of immunocompetence by GM-CSF or IFN[gamma] after pharmacological suppression

  2000cites this paper
• Immunologic Aspects of Transplant Management: Pharmacotherapy and Rejection

  2000cites this paper
• Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial.

  2000cites this paper
• Immunosuppressive agents in organ transplantation: past, present, and future.

  2000cites this paper
• Current treatment practice in immunosuppression

  2000cites this paper
• Liver transplantation of patients in end-stage cirrhosis.

  2000cites this paper
• Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin.

  2000cites this paper
• Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.

  1999cites this paper
• Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.

  1999cites this paper
• Tacrolimus and mycophenolate mofetil regimens in transplantation: benefits and pitfalls.

  1999cites this paper
• Newer immunosuppressive drugs: a review.

  1999cites this paper
• Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.

  1999cites this paper
• Tacrolimus and Mycophenolate Mofetil Regimens in Transplantation

  1999cites this paper
• The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.

  1999cites this paper
• Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.

  1999cites this paper
• [Liver transplantation].

  1998cites this paper
• Pregnancy after liver transplantation.

  1998cites this paper
• Mycophenolate mofetil (Cellcept).

  1998cites this paper